ABL Europe, the European contract manufacturing arm of ABL, has entered into a supply partnership with Sartorius Stedim Biotech to equip its viral vector manufacturing facility with end-to-end single-use equipment.
The GMP drug substance site in Strasbourg, France will benefit from single-use bioreactors, an automation platform for normal flow filtration, tangential filtration and mixing, and will be used to support customers’ oncolytic, vaccine and gene therapy projects.
The 16,000 sq ft facility houses four controlled and segregated manufacturing suites and offers both clinical and commercial production.
“The introduction of non-adherent cell culture capacity complements our existing adherent cell culture viral vector production technologies,” said Patrick Mahieux, general manager of ABL Europe
“It is the only pure-play, dedicated viral vector production site capable of manufacturing drug substance and drug product materials for toxicological studies, all clinical phases and even commercial launch. Everything from process development, manufacturing and QC release testing is performed under one roof.”